GlassScriptPhysician profile
Olga M Mas
NPI 1154358000
$2,068.68
in general payments reported to CMS, 2019-2025
22 companies · $327 in 2025
The $327 reported for 2025 was more than what 86% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $114 · 2021: $296 · 2022: $439 · 2023: $346 · 2024: $305 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $418.60 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $409.25 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $183.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $163.76 | 2023-2024 | Flumist Quadrivalent, Evusheld |
| Sobi, INC | $160.97 | 2019-2024 | |
| Glaxosmithkline, LLC. | $118.98 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $96.29 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $78.94 | 2019-2025 | Cotempla Xr-Odt |
| Kaleo, INC. | $77.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $53.16 | 2020-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Sanofi Pasteur INC. | $51.41 | 2021-2025 | |
| Biomarin Pharmaceutical INC. | $48.91 | 2025 | Voxzogo 1.2mg |
| Pfizer INC. | $46.15 | 2021-2023 | |
| Cranial Technologies, INC | $37.06 | 2021-2022 | |
| Seqirus USA INC | $28.29 | 2021-2025 | Flucelvax |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $24.60 | 2024 | Xelstrym |
| Corium, LLC | $24.37 | 2022-2023 | Azstarys |
| Mylan Pharmaceuticals INC. | $12.50 | 2019 | |
| Shire North American Group INC | $12.14 | 2019 | |
| Tris Pharma INC | $11.15 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,002,499.99 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Mas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.